Viewing
News|Articles|November 22, 2026

BL1332 misses primary end point in phase 2 post-PRK ocular pain study

BL1332 (Bausch + Lomb), a first-in-class topical TRPV1 antagonist, did not meet its primary end point in a phase 2 study of ocular pain following photorefractive keratectomy (PRK), although both doses produced numerically greater pain relief than vehicle across every SPID analysis, according to a new announcement. In exploratory analyses, more patients achieved complete pain relief with BL1332, and treated eyes showed signs of faster corneal epithelial recovery.1

No approved therapy is currently designed specifically to target the neurosensory pathways driving ocular surface pain, according to the company. The phase 2 readout builds on an earlier phase 1b capsaicin challenge study, in which BL1332 0.30% met its primary end point by significantly reducing pain intensity versus vehicle in healthy participants.2 Bausch + Lomb plans to discuss the full dataset with the FDA, including potential phase 3 planning.1

BL1332 phase 2 trial design and primary end point results a

fter PRK

The randomized, double-masked, vehicle-controlled, parallel-group study (NCT07412496) enrolled 129 adults undergoing unilateral sequential PRK for myopia.1 Participants were randomized 2:2:1 to BL1332 0.30%, BL1332 0.15% or vehicle, with treatment beginning immediately after surgery; the modified intent-to-treat population included 50, 49 and 27 patients, respectively.3 Patients received 5 doses over 24 hours while awake for 3 days, with follow-up through day 14.1

SPID, a time-weighted sum of changes in 0-to-10 numeric pain rating scale scores from presurgery baseline, served as the primary analysis, with lower values indicating less pain. In additional results presented during a November 19 Bausch + Lomb research and development webcast, the least-squares mean difference versus vehicle over 24 hours was –11.5 (90% CI, –27.4 to 4.4; P = .233) for BL1332 0.30% and –9.0 (90% CI, –24.9 to 6.9; P = .353) for BL1332 0.15%.1,3

For the 0- to 6-hour SPID secondary end point, BL1332 0.30% showed a difference of –4.2 versus vehicle (90% CI, –8.4 to –0.04; P = .097), a nominal result at a two-sided α of .10 the company characterized as supportive rather than confirmatory. The 0.15% dose did not separate from vehicle over the same window (P = .497). In post hoc exploratory analyses without multiplicity adjustment, 0- to 72-hour SPID differences were –31.8 (P = .113) and –24.4 (P = .221) for the 0.30% and 0.15% doses, respectively, extending a numerical advantage seen in every SPID window.3

Complete pain relief, corneal healing and safety findings for BL1332

At every assessment between 6 and 12 hours after surgery, a greater proportion of patients in either BL1332 arm reported complete pain relief, defined as a numeric pain rating scale score of 0, compared with vehicle. At 6 hours, complete pain relief rates were 14.0% with BL1332 0.30% and 14.6% with BL1332 0.15%, vs 3.7% with vehicle, and at 12 hours the rates were 10.2% and 12.5% vs 0%.1,3 At 24 hours, rates were 8.0% and 6.1% vs 7.4% with vehicle.3

At 72 hours, 70.8% of patients receiving BL1332 0.30% and 59.2% receiving BL1332 0.15% reported no pain vs 53.8% with vehicle, which the company described as a dose response.3 In an anterior segment optical coherence tomography subset, both BL1332 doses were associated with greater central corneal epithelial thickness at day 3 compared with vehicle. The company described the finding as consistent with faster healing of the corneal surface and said it supports further evaluation in future studies.1

BL1332 was well tolerated, according to the company. Treatment-emergent adverse events occurred in 6.0% of patients receiving BL1332 0.30%, 13.7% receiving BL1332 0.15% and 14.8% receiving vehicle. No treatment-related adverse events, serious adverse events or discontinuations due to adverse events occurred, and no new safety signals emerged.1

Ahead of the readout, Yehia Hashad, MD, chief medical officer and executive vice president of research and development at Bausch + Lomb, framed the phase 2 study as the next test of the mechanism. "The phase 1b study established proof of mechanism in humans. The ongoing phase 2 study will add important information about how BL1332 performs in patients experiencing clinically relevant pain," he told Ophthalmology Times in a September Q&A.4

During the webcast question-and-answer session, Hashad said a go/no-go decision will depend on discussions with health authorities, and the company plans to share its development plans with regulators for feedback. He added repeating a phase 2 study without enlarging the sample size would likely produce the same answers, and the next step should instead be a study powered as a pivotal trial.3

According to Hashad, the phase 2 study answered 4 core questions: whether BL1332 showed a clear efficacy signal, whether its safety profile was favorable, whether one dose separated enough to move forward and whether the magnitude of effect justified a larger confirmatory study. He answered yes to each. "So doing another Phase 2, I don't think so. So the next phase, we should think of a larger confirmatory study," Hashad said.3

Bausch + Lomb is also evaluating study designs, end points and patient populations following the phase 2 results.1 In the earlier interview, Hashad identified patients with dry eye disease experiencing significant ocular pain as one potential future population for the TRPV1 approach.4

Frequently Asked Questions

What is BL1332?

BL1332 is an investigational, first-in-class topical TRPV1 antagonist from Bausch + Lomb designed to block a key receptor in ocular pain signaling. Its first patient study evaluated pain after PRK.

How does BL1332 work?

BL1332 antagonizes TRPV1, one of the primary pain sensors on the ocular surface, with the goal of interrupting pain signaling directly rather than treating an associated sign such as inflammation.

What did the BL1332 phase 2 trial show?

BL1332 missed its 24-hour SPID primary end point (P = .233 for 0.30%; P = .353 for 0.15%), although both doses produced numerically greater pain relief than vehicle across all SPID analyses. The 0.30% dose showed a nominal pain reduction over the first 6 hours (P = .097 at a two-sided α of .10).

What are the next steps for BL1332?

Bausch + Lomb plans to discuss the phase 2 data with the FDA. According to Hashad, the company expects the next step to be a larger confirmatory study rather than a second phase 2 trial, pending FDA feedback.

References
1. Bausch + Lomb Corporation. Bausch + Lomb reports phase 2 findings for BL1332 in post-surgical ocular pain. News release. Business Wire. November 19, 2026. Accessed November 20, 2026. https://www.businesswire.com/news/home/20261118969505/en/Bausch-Lomb-Reports-Phase-2-Findings-for-BL1332-in-Post-Surgical-Ocular-Pain
2. Bausch + Lomb Corporation. Bausch + Lomb advancing two first-in-class eye health therapies based on trial results. News release. August 24, 2026. Accessed November 20, 2026. https://www.bausch.com/newsroom/news/?id=361
3. Hashad Y, Attar M. BL1332 ocular surface pain R&D update. Presented at: Bausch + Lomb webcast; November 19, 2026. Accessed November 20, 2026. https://www.webcaster5.com/Webcast/Page/2883/54869
4. Hashad Y, Gambuzza L. BL1332 clears phase 1b: Yehia Hashad, MD, on what's next. Ophthalmology Times. September 2, 2026. Accessed November 20, 2026. https://www.ophthalmologytimes.com/view/bl1332-clears-phase-1b-yehia-hashad-md-on-what-s-next

Related to this article